Adamas Therapy Improves Multiple Sclerosis Patients’ Walking Speed, Trial Shows

Adamas Therapy Improves Multiple Sclerosis Patients’ Walking Speed, Trial Shows

The walking speed of multiple sclerosis patients taking Adamas Pharmaceuticals’ ADS-5102 (amantadine) increased by 16.6 percent more those taking a placebo, a Phase 2 clinical trial reports.

Another finding was that more of the treated patients increased their walking speed by 20 percent or more during the four-week trial.

The study, “Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial,” was published in the Multiple Sclerosis Journal.

Adamas said the proof-of-concept trial (NCT02471222) at 14 U.S. centers involved 60 patients with walking impairments. Researchers randomized them so that 30 received ADS-5102 and 30 a placebo.

Patients took a tablet a day at bedtime. In the first week, participants received 137-mg tablets. After that, it was 274-mg doses.

The trial’s primary objective was to evaluate ADS-5102’s safety and patients’ ability to tolerate it. Secondary objectives included seeing if ADS-5102 would improve patients’ overall mobility and walking ability. Researchers used four measurements: Patients’ scores on a timed 25-foot walk test, timed up and go test, two-minute walk test, and MS walking scale 12.

Treated patients’ timed 25-foot walk test score was 16.6 percent higher than the placebo group’s — a result considered significant. The test covers both mobility and leg function performance.

In addition, treated patients fared better than the controls in the timed up and go and two-minute walk tests, “although the differences were not significant,” the researchers wrote. The up and go test uses balance to assess mobility. As the name two-minute walk test implies, it looks at the distance a person can walk in two minutes.

In terms of safety, patients generally tolerated ADS-5102 well, researchers said.

“In this proof-of-concept study, a greater proportion of ADS-5102 patients had at least a 20 percent improvement in walking speed compared with the placebo group,” Jeffrey A. Cohen, a Cleveland Clinic neurologist who was a consultant on the trial, said in a press release. Cohen is with the Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research.

“There is a need for additional, effective treatment options in this multiple sclerosis patient population, as currently there is only one FDA-approved drug, which is believed to be effective in only a subset of multiple sclerosis patients with walking impairment,” Cohen added.

Adamas plans to start a Phase 3 clinical trial this year of ADS-5102’s ability to help MS patients.

“We are pleased to have data from this important study available in a peer-reviewed journal and look forward to initiating the first Phase 3 clinical study of ADS-5102 in multiple sclerosis patients with walking impairment in the second quarter of 2018,” Rajiv Patni, the company’s chief medical officer.


  1. Merichel says:

    The problem with this is that the common side effects include:
    Agitation, anxiety, or nervousness
    difficulty concentrating
    loss of appetite
    purplish red, net-like, or blotchy spots on the skin
    trouble in sleeping or nightmares

    There are some days when I have a lot of dizziness because of MS. We need different therapies that take into account that. I use coffee and Yerba Mate (it has the tea benefits and also proteins, and a bit of caffeine) and it helps feel more energized better than those meds that have crazy side effects for people like me who deal with that part of the disease.


    My wife was on Amantadine for over 15 plus years and never had a problem. She was only taking 1 per day. She started losing her energy and the doctor suggested she take 2 per day to increase her energy..within a matter of a few days she she became unsteady on her feet which affected her balance.She was unable to write nor sign anything due to tremors which became much worse. Her cognitive function was all of a sudden getting worse. The worst was that her eyesight was getting very hazy and had problems seeing. We went to the Neuropathologist all he was able to determine was that her Corena’s were swollen. After two appointments and various eye drops as well as an antibiotic there was no change. He suggest we go to a Cornea specialist. We did. Within less than five minutes he was able to determine the cause was the Amantadine. He told her to stop taking it as one of the side effects is loss of vision. This side effect is rare. After two weeks she regained everything she lost. The plus side is her sight returned and the tremors disappeared, overall health improved including some of the problems with the MS. It seems even the one pill a day effected her and it was the Amantadine.

  3. Peter says:

    I have been taking Amantadine for maybe 18 years. Now I take 2 pills a day – 1 in the morning and 1 after a lunch. I do not take it in the evening, because of problems with sleeping.
    Amantadine gives me more energy for almost whole day. I can not found any side effect on me mentioned above. For me it is one of the drugs a must.

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This